Soliris (eculizumab), Concentrated solution for intravenous infusion

Soliris is a complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Brand: Soliris (eculizumab), Concentrated solution for intravenous infusion Initial U.S. Approval: 2007

Home | (eculizumab), Concentrated solution

Soliris (eculizumab) Price In India and Overseas
Soliris (eculizumab), Concentrated solution

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Soliris (eculizumab), Concentrated solution

Eculizumab is used to treat atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH)

Soliris, A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal hemoglobinuria (PNH). It is also used to treat another rare disorder called atypical hemolytic urea syndrome (aHUS), in which blood clots form in small blood vessels. Soliris binds to an immune system protein called C5. This helps keep red blood cells from breaking down and helps keep blood clots from forming. Soliris is a type of monoclonal antibody. Also called eculizumab.

Eculizumab, A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal hemoglobinuria (PNH). It is also used to treat another rare disorder called atypical hemolytic urea syndrome (aHUS), in which blood clots form in small blood vessels. Eculizumab binds to an immune system protein called C5. This helps keep red blood cells from breaking down and helps keep blood clots from forming. Eculizumab is a type of monoclonal antibody. Also called Soliris.

Drug (Brand / Generic): Soliris / eculizumab
Current Indications: paroxysmal nocturnal hemoglobinuria (PNH)
Marketed by:: Alexion Pharmaceuticals, Inc
Approval Date: 2007

Available as (Form & Strength): 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.